Celularity Inc (CELU): R&D Expense
$15.03M
Year ended 2025-12-31
-42.3%
3-year compound annual growth
-22.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.03M | -13.6% | 2026-04-30, From 2025-01-01 |
| 2024-12-31 | $17.39M | -42.9% | 2026-04-30, From 2024-01-01 |
| 2023-12-31 | $30.46M | -61.1% | 2025-05-08, From 2023-01-01 |
| 2022-12-31 | $78.36M | -11.3% | 2024-07-30, From 2022-01-01 |
| 2021-12-31 | $88.35M | +67.6% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $52.71M | n/a | 2022-03-31, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Celularity Inc (CELU) | 2025-12-31 | $15.03M | -13.6% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $37.74M | +4.0% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $142.27M | +13.5% |
| Alumis Inc. (ALMS) | 2025-12-31 | $386.00M | +45.4% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $85.47M | -9.6% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $114.60M | +40.9% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $141.83M | -6.3% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $7.17M | -1.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $6.31M | -29.3% |
Compare CELU, CUE, TRDA, ALMS side by side · Screen every company in Pharmaceutical Preparations ↗